Therapeutic targets of renin-angiotensin system in ocular disorders
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PURPOSE: To review current literature on the renin-angiotensin system (RAS)-mediated pathogenic mechanisms and therapeutic targets in ocular diseases. METHODS: A comprehensive literature survey was performed on PubMed, Scopus, and Google Scholar databases published from 1977 to 2016. The search terms were a RAS, angiotensin, angiotensin receptor, prorenin, pro (renin) receptor, angiotensin converting enzyme inhibitor, angiotensin receptor blocker associated with ocular disorders like cataract, glaucoma, diabetic retinopathy (DR), macular degeneration, and uveitis. Articles were reviewed on the basis of the association between ocular disorders and RAS and relevant articles were discussed. RESULTS: The literature revealed that the individual RAS components including renin, angiotensins, angiotensin converting enzymes, and RAS receptors have been expressed in the specific ocular tissues like retina, choroid, and ciliary body. The activation of both circulatory and local RAS potentiate the various inflammatory and angiogenic signaling molecules, including vascular endothelial growth factor (VEGF), extracellular signal-regulated kinase, and advanced glycation end products (AGE) in the ocular tissues and leads to several blinding disorders like DR, glaucoma, and macular degeneration. The classical and newer RAS inhibitors have illustrated protective effects on blinding disorders, including DR, glaucoma, macular degeneration, uveitis, and cataract. CONCLUSIONS: The RAS components are present in the extrarenal tissues including ocular tissue and have an imperative role in the ocular pathophysiology. The clinical studies are needed to show the role of therapeutic modalities targeting RAS in the treatment of different ocular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Tsutsumi, C., Sonoda, K.-H., Egashira, K., Qiao, H., Hisatomi, T., Nakao, S., Ishibashi, M., Charo, I. F., Sakamoto, T., Murata, T., et al. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0902436 · Cited by 277
Nabah, Y. N. A., Mateo, T., Estellés, R., Mata, M., Zagorski, J., Sarau, H., Cortijo, J., Morcillo, E. J., Jose, P. J., & Sanz, M.-J. (2004) · Circulation · doi:10.1161/01.cir.0000148824.93600.f3 · Cited by 124
Cited by
Phipps, J. A., Dixon, M. A., Jobling, A. I., Wang, A. Y., Greferath, U., Vessey, K. A., & Fletcher, E. L. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107753 · Cited by 48
Suzumura, A., Terao, R., & Kaneko, H. (2020) · Antioxidants · doi:10.3390/antiox9100920 · Cited by 44
“Abbreviations 17-HDHA 17-hydroxy docosahexaenoic acid 18-HEPE 18-hydroxyeicosapentaenoic acid A2E N-retinyl-N-retinylidene ethanolamine AA arachidonic acid ALA α-linolenic acid AMD age-related macular degeneration ANG-II angiotensin II AREDS the Age-Related Eye Disease Study AT-RvD aspirin-triggered resolvin D BDNF br…”
BackgroundInfluential
Metadata
- Authors
- Choudhary, R., Kapoor, M. S., Singh, A., & Bodakhe, S. H.
- Venue
- Journal of Current Ophthalmology
- Publisher
- Medknow
- Published
- 2017-03
- Volume
- 29
- Issue
- 1
- Pages
- 7-16
- ISSN
- 2452-2325 (ISSN-L)
- OpenAlex
- W2534441626
- Cited by
- 158
- References
- 5
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.